Personal information

Uganda

Biography

I am an infectious diseases expert with a focus on pathogenesis, diagnostics, and program implementation using both conventional microbiological methods and modern molecular approaches. In this regard, I have acquired the necessary skills and established a laboratory-based research capacity in Uganda. I have acquired advanced skills in Molecular Epidemiology and Bioinformatics. I hold an Erasmus Mundus Ph.D. in Molecular Microbiology from the Universities of Amsterdam (Academic Medical Centre), the Netherlands, and Barcelona, Spain with laboratory training at the Institute of Tropical Medicine (ITM), Antwerp, Belgium. I have over 15 years of experience working on projects and training grants relating to TB and HIV in Africa.

I have participated in several international clinical trials and studies including the AIDS Clinical Trials Group (ACTG), Tuberculosis Vaccine Trials Group, Tuberculosis Clinical Diagnostic Research Consortium (TBCDRC), International Maternal, Paediatric, and Adolescent AIDS Clinical Trials (IMPAACT) Network. I have also participated in Diagnostic validation studies including; LAM, Epistem/MolBio True-NAAT, LAMP, XpertULTRA, BDMax, SMF, XpertXDR-TB, etc. Clinical trials including; PROMPT, NC-005, NC-006, NC-008, STREAM2, ACTG/IMPAACT trials [P1108, IMPAACT 2020, A5300B, IMPAACT 2003B / A5300B (PHOENIx), A5349, A5274], SHINE trials, among others as a key person in different positions ranging from technical supervision to principal investigator.

I have trained and supervised 14 master’s students to completion so far, six ongoing and in their final stages, and four Ph.D. students in good progress. I have trained and mentored a number of non-degree students and fellows and most of my students end up taking influential positions in their careers. I have also trained and supervised personnel from a number of laboratories in TB laboratory experiments in Uganda and beyond. I have organized several training programs both at Makerere University and beyond, for students and researchers. Since 2018 to date, I have offered consultancy services to the World Health Organization and USAID as a senior international TB laboratory expert on different aspects. I have offered several invited speeches as well as over 15 international abstract presentations on TB/HIV including general aspects of infectious diseases. During my career development, I won a number of academic awards/ scholarships including research grants, and gained experience which I continue to pass on to my mentees. I have contributed to the establishment of the BSL-3 facility at Makerere University with acceptable international standards in a resource-limited setting. This BSL-3 facility has been College of American Pathologists (CAP) accredited since 2014 and it is the laboratory of choice for most TB research groups. I have contributed to over 80 peer-reviewed publications and 5 book chapters in top-rated peer-reviewed journals.

Activities

Employment (6)

Makerere University : Kampala, Kampala, UG

2016-01-01 to present | Scientific Director (Medical Microbiology, Mycobacteriology ( BSL-3) facility)
Employment
Source: Self-asserted source
Willy Ssengooba, PhD.

Makerere University: Kampala, Kampala, UG

2013-09-01 to 2015-12-01 | Laboratory Consultant (Medical Microbiology, Mycobacteriology ( BSL-3) Laboratory)
Employment
Source: Self-asserted source
Willy Ssengooba, PhD.

Makerere University College of Health Sciences: Kampala, Kampala, UG

2009-10 to 2015-12-01 | Consultant , Mycobacteriology (BSL-3) Laboratory (Medical Microbiology)
Employment
Source: Self-asserted source
Willy Ssengooba, PhD.

Makerere University College of Health Sciences: Kampala, Kampala, UG

2011-03 to 2013-08-31 | Manager- Mycobacteriology (BSL-3) Laboratory (Medical Microbiology)
Employment
Source: Self-asserted source
Willy Ssengooba, PhD.

Makerere University Infectious Diseases Institute: Kampala, Kampala, UG

2008-01 to 2012-02 | Infectious Diseases Institute (IDI)Laboratory Manager- Uganda TB vaccine studies/BSL-3 TB facility (Tuberculosis Research Consortium)
Employment
Source: Self-asserted source
Willy Ssengooba, PhD.

National TB and Leprosy Program, Ministry of Health: Kampala, UG

2006-04 to 2007-12 | QA\QC Manager (National TB Reference Laboratory)
Employment
Source: Self-asserted source
Willy Ssengooba, PhD.

Education and qualifications (3)

University of Amsterdam: Amsterdam, NL

2013-09-01 to 2017-06-13 | PhD (Molecular Microbiology) (Academic Medical Center)
Education
Source: Self-asserted source
Willy Ssengooba, PhD.

Makerere University: Kampala, Kampala, UG

2009-09 to 2011-09 | Master of Health Services Research ( Clinical Microbiology)
Education
Source: Self-asserted source
Willy Ssengooba, PhD.

Makerere University: Kampala, Kampala, UG

2001-09 to 2005-09 | Bachelor of Biomedical Sciences (Biomedical Sciences)
Education
Source: Self-asserted source
Willy Ssengooba, PhD.

Professional activities (1)

International Union Against Tuberculosis and Lung Disease: Geneva, CH

2016-11-01 to present
Membership
Source: Self-asserted source
Willy Ssengooba, PhD.

Funding (3)

Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV

2020-10-01 to 2024-09-30 | Grant
European & Developing Countries Clinical Trials Partnership (The Hague, NL)
GRANT_NUMBER:

RIA2018D-2511

Source: Self-asserted source
Willy Ssengooba, PhD. via DimensionsWizard

Evaluation of alternative bacteriological measures of response to therapy during the initial 16-weeks of MDR-TB treatment

2019-11-01 to 2022-10-31 | Grant
European & Developing Countries Clinical Trials Partnership (The Hague, NL)
GRANT_NUMBER:

TMA2018CDF-2351

Source: Self-asserted source
Willy Ssengooba, PhD. via DimensionsWizard

Consequences of Mycobacterium tuberculosis genetic diversity in the context of HIV co-infection for laboratory diagnosis of tuberculosis in Africa

2014-04-28 to 2017-06-13 | Grant
Belgian Federal Science Policy Office (Brussels, BE)
Source: Self-asserted source
Willy Ssengooba, PhD. via DimensionsWizard

Works (50 of 91)

Items per page:
Page 1 of 2

Antimycobacterial Activities of the <i>Zanthoxylum leprieurii</i> Metabolite Adubangoamide and Non-Natural Fagaramide Analogues.

Journal of natural products
2025-02-11 | Journal article
Contributors: Oloya B; Namukobe J; Krüger M; Ssengooba W; Sperlich E; Kwesiga G; Komakech K; Heydenreich M; Byamukama R; Bernd Schmidt
Source: Self-asserted source
Willy Ssengooba, PhD.

Uptake and rollout of the World Health Organization-endorsed technologies for Tuberculosis diagnosis in Africa: A systematic review of international evidence 2007-2021

2025-02-07 | Preprint
Contributors: Jean de Dieu Iragena; Esther Uwimaana; Derrick Semugenze; Kevin Komakech; Achilles Katamba; Anandi Martin; Moses Joloba; Willy Ssengooba
Source: check_circle
Crossref

Performance of stool-based molecular tests and processing methods for paediatric tuberculosis diagnosis: a systematic review and meta-analysis.

The Lancet. Microbe
2024-11-09 | Journal article
Contributors: Carratalà-Castro L; Munguambe S; Saavedra-Cervera B; de Haas P; Kay A; Marcy O; Nabeta P; Ssengooba W; Ghimenton-Walters E; Acácio S et al.
Source: Self-asserted source
Willy Ssengooba, PhD.

Non-sputum-based samples and biomarkers for detection of Mycobacterium tuberculosis: the hope to improve childhood and HIV-associated tuberculosis diagnosis

European Journal of Medical Research
2024-10-18 | Journal article
Part of ISSN: 2047-783X
Contributors: George W. Kasule; Sabine Hermans; Derrick Semugenze; Enock Wekiya; Joachim Nsubuga; Patricia Mwachan; Joel Kabugo; Moses Joloba; Alberto L. García-Basteiro; Willy Ssengooba et al.
Source: Self-asserted source
Willy Ssengooba, PhD.

Airway microbiome signature accurately discriminates Mycobacterium tuberculosis infection status

iScience
2024-05 | Journal article
Part of ISSN: 2589-0042
Contributors: Alex Kayongo; Moses Levi Ntayi; Geoffrey Olweny; Edward Kyalo; Josephine Ndawula; Willy Ssengooba; Edgar Kigozi; Robert Kalyesubula; Richard Munana; Jesca Namaganda et al.
Source: Self-asserted source
Willy Ssengooba, PhD.

Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries.

Nature communications
2024-05-10 | Journal article | Author
Contributors: Biljana Kakaraskoska Boceska; Vilken T; Xavier BB; Kostyanev T; Lin Q; Lammens C; Ellis S; O'Brien S; da Costa RMA; Cook A et al.
Source: Self-asserted source
Willy Ssengooba, PhD.

Clinical outcomes in children living with HIV treated for non-severe tuberculosis in the SHINE Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
2024-04-09 | Journal article
Contributors: Chishala Chabala; eric wobudeya; van der Zalm MM; Kapasa M; Priyanka Raichur; Mboizi R; Megan Palmer; AARTI KINIKAR; Hissar S; Veronica Mulenga et al.
Source: Self-asserted source
Willy Ssengooba, PhD.
grade
Preferred source (of 2)‎

A Global Tuberculosis Dictionary: unified terms and definitions for the field of tuberculosis.

The Lancet. Global health
2024-03-22 | Journal article
Contributors: Garcia-Basteiro AL; Ehrlich J; Bonnet M; Calnan M; Graham SM; Hermans S; Jarrett A; Lewa R; Mandalakas A; Martinez L et al.
Source: Self-asserted source
Willy Ssengooba, PhD.

Accuracy of the tuberculosis molecular bacterial load assay to diagnose and monitor response to anti-tuberculosis therapy: a longitudinal comparative study with standard-of-care smear microscopy, Xpert MTB/RIF Ultra, and culture in Uganda.

The Lancet. Microbe
2024-03-05 | Journal article
Contributors: Musisi E; Wamutu S; Ssengooba W; Kasiinga S; Sessolo A; Sanyu I; Kaswabuli S; Zawedde J; Byanyima P; Kia P et al.
Source: Self-asserted source
Willy Ssengooba, PhD.

Predisposing, enabling, and need factors influencing rapid uptake of the World Health Organization-endorsed TB diagnostic technologies in Africa

2024-03-04 | Preprint
Contributors: Jean de Dieu Iragena; Achilles Katamba; Anandi Martin; Moses Joloba; Willy Ssengooba
Source: check_circle
Crossref

A stool based qPCR for the diagnosis of TB in children and people living with HIV in Uganda, Eswatini and Mozambique (Stool4TB): a protocol for a multicenter diagnostic evaluation.

BMC infectious diseases
2024-02-21 | Journal article
Contributors: Carratala-Castro L; Ssengooba W; Kay A; Acácio S; Ehrlich J; DiNardo AR; Shiba N; Nsubuga JK; Munguambe S; Saavedra-Cervera B et al.
Source: Self-asserted source
Willy Ssengooba, PhD.

Performance evaluation of Truenat MTB and Truenat MTB-RIF DX assays in comparison to gene XPERT MTB/RIF ultra for the diagnosis of pulmonary tuberculosis in Uganda.

BMC infectious diseases
2024-02-13 | Journal article
Contributors: Ssengooba W; Katamba A; Sserubiri J; Semugenze D; Nyombi A; Byaruhanga R; Turyahabwe S; Joloba ML
Source: Self-asserted source
Willy Ssengooba, PhD.

Effect of mixed Mycobacterium tuberculosis infection on rapid molecular diagnostics among patients starting MDR-TB treatment in Uganda.

BMC infectious diseases
2024-01-10 | Journal article
Contributors: Komakech K; Nakiyingi L; Fred A; Achan B; Joloba M; Kirenga BJ; Ssengooba W
Source: Self-asserted source
Willy Ssengooba, PhD.

Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials.

The Lancet. Microbe
2023-10-10 | Journal article
Contributors: Musisi E; Wyness A; Eldirdiri S; Dombay E; Mtafya B; Ntinginya NE; Heinrich N; Kibiki GS; Hoelscher M; Boeree M et al.
Source: Self-asserted source
Willy Ssengooba, PhD.

Geographic distribution and predictors of diagnostic delays among possible TB patients in Uganda

Public Health Action
2023-09-21 | Journal article
Part of ISSN: 2220-8372
Contributors: E. Ochom; K. O. Robsky; A. J. Gupta; A. Tamale; J. Kungu; P. Turimumahoro; S. Nakasendwa; I. B. Rwego; W. Muttamba; M. Joloba et al.
Source: Self-asserted source
Willy Ssengooba, PhD.

Evaluation of Xpert MTB/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in Uganda

PLOS ONE
2023-08-17 | Journal article
Contributors: Achilles Katamba; Padmapriya P Banada; Willy Ssengooba; James Sserubiri; Derrick Semugenze; George William Kasule; Abdunoor Nyombi; Raymond Byaruhanga; Stavia Turyahabwe; Moses L. Joloba
Source: check_circle
Crossref

Inadequate Lopinavir Concentrations With Modified 8-hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV.

The Pediatric infectious disease journal
2023-07-20 | Journal article
Contributors: Chishala Chabala; Anna Turkova; Kapasa M; LeBeau K; Tembo CH; Zimba K; Weisner L; Khozya Zyambo; Louise Choo; Chalilwe Chungu et al.
Source: Self-asserted source
Willy Ssengooba, PhD.

Two new compounds and the anti-mycobacterial activity of the constituents from Zanthoxylum leprieurii root bark

Phytochemistry Letters
2023-04 | Journal article
Contributors: Benson Oloya; Jane Namukobe; Matthias Heydenreich; Willy Ssengooba; Johannes Martin; Heiko Michael Möller; Bernd Schmidt; Robert Byamukama
Source: check_circle
Crossref

Evaluation of Xpert®MTB/XDR test for susceptibility testing ofMycobacterium tuberculosisto first and second-line drugs in Uganda

2023-04-05 | Preprint
Contributors: Achilles Katamba; Willy Ssengooba; James Sserubiri; Derrick Semugenze; Kasule George William; Nyombi Abdunoor; Raymond Byaruhanga; Stavia Turyahabwe; Moses L Joloba
Source: check_circle
Crossref

Lots of considerations when evaluating the FujiLAM assay.

The Lancet. Global health
2023-04-01 | Journal article
Contributors: Garcia-Basteiro AL; Cobelens F; Ssengooba W; Theron G
Source: Self-asserted source
Willy Ssengooba, PhD.

Second-line drug resistance markers as proxy indicators of time to sputum culture conversion among second-line drug resistant tuberculosis patients tested in Uganda: A cross-sectional study [version 1; peer review: 1 approved with reservations, 1 not approved]

2023-01-16 | Journal article
Part of ISSN: 2046-1402
Contributors: Dennis Mujuni; Willy Ssengooba; Ivan Ibanda; Joel Solomon Kabugo; Dianah Linda Kasemire; Elizabeth Nampewo; Andrew Nsawotebba; Jody E Phelan; Didas Tugumisirize; Beatrice Orena et al.
Source: check_circle
F1000
grade
Preferred source (of 2)‎

Cardiovascular risk factors among people with drug-resistant tuberculosis in Uganda.

BMC cardiovascular disorders
2022-11-04 | Journal article
Contributors: Willy Ssengooba, PhD.; Baluku JB; Nabwana M; Nalunjogi J; Muttamba W; Mubangizi I; Nakiyingi L; Ssengooba W; Olum R; Bongomin F et al.
Source: Self-asserted source
Willy Ssengooba, PhD.

Quantification of multidrug-resistant <i>M. tuberculosis</i> bacilli in sputum during the first 8 weeks of treatment.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
2022-11-01 | Journal article
Contributors: Willy Ssengooba, PhD.; Smith-Jeffcoat SE; Eisenach KD; Joloba M; Ssengooba W; Namaganda C; Nsereko M; Okware B; Cavanaugh JS; Cegielski JP
Source: Self-asserted source
Willy Ssengooba, PhD.

Prevalence and antimicrobial resistance profiles of Neisseria gonorrhea and Chlamydia trachomatis isolated from individuals attending STD clinics in Kampala, Uganda.

African health sciences
2022-09-01 | Journal article
Contributors: Nakku-Joloba E; Gerald Mboowa; Ssengooba W; Kiyimba A; Kigozi E; Baluku H; Alinaitwe L; Nyote R; Kabahita JM; Mutumba P et al.
Source: Self-asserted source
Willy Ssengooba, PhD.

Strategies to Reduce Mortality Among Children Living With HIV and Children Exposed to HIV but Are Uninfected, Admitted With Severe Acute Malnutrition at Mulago Hospital, Uganda (REDMOTHIV): A Mixed Methods Study.

Frontiers in pediatrics
2022-06-24 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.

Recurrent pneumothorax in a human immunodeficiency virus-positive patient with multidrug-resistant tuberculosis: a rare case of bronchopleural fistula: a case report.

Journal of medical case reports
2022-05-31 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.

Molecular characterisation of second-line drug resistance among drug resistant tuberculosis patients tested in Uganda: a two and a half-year's review.

BMC infectious diseases
2022-04-11 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.

Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children.

The New England journal of medicine
2022-03-01 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.

High Mycobacterium tuberculosis Bacillary Loads Detected by Tuberculosis Molecular Bacterial Load Assay in Patient Stool: a Potential Alternative for Nonsputum Diagnosis and Treatment Response Monitoring of Tuberculosis.

Microbiology spectrum
2022-01-12 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.

Performance and cost-effectiveness of a pooled testing strategy for SARS-CoV-2 using real-time polymerase chain reaction in Uganda

International Journal of Infectious Diseases
2021-12 | Journal article
Contributors: Naghib Bogere; Felix Bongomin; Andrew Katende; Kenneth Ssebambulidde; Willy Ssengooba; Henry Ssenfuka; Edgar Kigozi; Samuel Biraro; David P. Kateete; Irene Andia-Biraro
Source: check_circle
Crossref

Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
2021-12 | Journal article
Part of ISSN: 2405-5794
Source: Self-asserted source
Willy Ssengooba, PhD.

Sputum microbiota profiles of treatment-naïve TB patients in Uganda before and during first-line therapy.

Scientific reports
2021-12-29 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.

Impact of the bacillary load on the accuracy of rifampicin resistance results by Xpert<sup>®</sup> MTB/RIF.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
2021-11-01 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.

Improving empiric antibiotic prescribing in pediatric bloodstream infections: a potential application of weighted-incidence syndromic combination antibiograms (WISCA)

Expert Review of Anti-infective Therapy
2021-09-15 | Journal article
Part of ISSN: 1478-7210
Part of ISSN: 1744-8336
Source: Self-asserted source
Willy Ssengooba, PhD.

Antimycobacterial Activity of the Extract and Isolated Compounds From the Stem Bark of Zanthoxylum leprieurii Guill. and Perr.

Natural Product Communications
2021-08 | Journal article
Part of ISSN: 1934-578X
Part of ISSN: 1555-9475
Source: Self-asserted source
Willy Ssengooba, PhD.

Assessing a transmission network of Mycobacterium tuberculosis in an African city using single nucleotide polymorphism threshold analysis.

MicrobiologyOpen
2021-06-01 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.

Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study.

BMC infectious diseases
2021-06-01 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.

Effectiveness of thermal screening in detection of COVID-19 among truck drivers at Mutukula Land Point of Entry, Uganda.

PloS one
2021-05-13 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.

Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda.

Open forum infectious diseases
2021-04-02 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.
grade
Preferred source (of 2)‎

The simple direct slide method is comparable to indirect Lowenstein Jensen proportion culture for detecting rifampicin resistant tuberculosis.

Journal of medical microbiology
2021-02-23 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.

Chest X-ray interpretation does not complement Xpert MTB/RIF in diagnosis of smear-negative pulmonary tuberculosis among TB-HIV co-infected adults in a resource-limited setting.

BMC infectious diseases
2021-01-13 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.

A sister lineage of the Mycobacterium tuberculosis complex discovered in the African Great Lakes region

Nature Communications
2020-12 | Journal article
Part of ISSN: 2041-1723
Source: Self-asserted source
Willy Ssengooba, PhD.
grade
Preferred source (of 2)‎

Accuracy of Xpert Ultra in Diagnosis of Pulmonary Tuberculosis among Children in Uganda: a Substudy from the SHINE Trial

Journal of Clinical Microbiology
2020-08-24 | Journal article
Contributors: Willy Ssengooba; Jean de Dieu Iragena; Lydia Nakiyingi; Serestine Mujumbi; Eric Wobudeya; Robert Mboizi; David Boulware; David B. Meya; Louise Choo; Angela M. Crook et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Typing and classification of non-tuberculous mycobacteria isolates [version 2; peer review: 1 approved, 1 approved with reservations]

2020-05-28 | Journal article
Part of ISSN: 2046-1402
Contributors: Thomas Clarke; Lauren Brinkac; Joanna Manoranjan; Alberto García-Basteiro; Harleen Grewal; Anthony Kiyimba; Elisa Lopez; Ragini Macaden; Durval Respeito; Willy Ssengooba et al.
Source: check_circle
F1000
grade
Preferred source (of 2)‎

High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda.

PloS one
2020-05-15 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.
grade
Preferred source (of 2)‎

Typing and classification of non-tuberculous mycobacteria isolates

F1000Research
2020-04-09 | Journal article
Contributors: Thomas Clarke; Lauren Brinkac; Joanna Manoranjan; Alberto García-Basteiro; Harleen Grewal; Anthony Kiyimba; Elisa Lopez; Ragini Macaden; Durval Respeito; Willy Ssengooba et al.
Source: check_circle
Crossref

Health seeking behavior among individuals presenting with chronic cough at referral hospitals in Uganda; Missed opportunity for early tuberculosis diagnosis

PLoS ONE
2019 | Journal article
EID:

2-s2.0-85066756204

Part of ISBN:

19326203

Contributors: Muttamba, W.; Ssengooba, W.; Kirenga, B.; Sekibira, R.; Walusimbi, S.; Katamba, A.; Joloba, M.
Source: Self-asserted source
Willy Ssengooba, PhD. via Scopus - Elsevier

Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance

Scientific Reports
2019-12 | Journal article
Part of ISSN: 2045-2322
Source: Self-asserted source
Willy Ssengooba, PhD.
grade
Preferred source (of 3)‎

Comparison of GeneXpert cycle threshold values with smear microscopy and culture as a measure of mycobacterial burden in five regional referral hospitals of Uganda- A cross-sectional study.

PloS one
2019-05-15 | Journal article
Source: Self-asserted source
Willy Ssengooba, PhD.
grade
Preferred source (of 2)‎

PO 8468 Determine TB–LAM lateral flow assay: does m. tuberculosis lineage influence its performance?

2019-04 | Journal article
Part of ISSN: 2059-7908
Source: Self-asserted source
Willy Ssengooba, PhD.
Items per page:
Page 1 of 2

Peer review (10 reviews for 3 publications/grants)

Review activity for BMC infectious diseases (4)
Review activity for Clinical infectious diseases : (1)
Review activity for PloS one. (5)